DE69716240T2 - Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten - Google Patents
Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhaltenInfo
- Publication number
- DE69716240T2 DE69716240T2 DE69716240T DE69716240T DE69716240T2 DE 69716240 T2 DE69716240 T2 DE 69716240T2 DE 69716240 T DE69716240 T DE 69716240T DE 69716240 T DE69716240 T DE 69716240T DE 69716240 T2 DE69716240 T2 DE 69716240T2
- Authority
- DE
- Germany
- Prior art keywords
- epitop
- nucleic acid
- vaccination
- contain
- new method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9602777.6A GB9602777D0 (en) | 1996-02-12 | 1996-02-12 | Delivery vehicle |
US1650696P | 1996-04-30 | 1996-04-30 | |
GBGB9614548.7A GB9614548D0 (en) | 1996-07-11 | 1996-07-11 | A delivery vehicle |
US2411696P | 1996-08-16 | 1996-08-16 | |
PCT/GB1997/000396 WO1997028818A1 (en) | 1996-02-12 | 1997-02-12 | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69716240D1 DE69716240D1 (de) | 2002-11-14 |
DE69716240T2 true DE69716240T2 (de) | 2003-06-26 |
Family
ID=27451395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69716240T Expired - Fee Related DE69716240T2 (de) | 1996-02-12 | 1997-02-12 | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0880360B1 (de) |
JP (1) | JP2000505802A (de) |
AT (1) | ATE225668T1 (de) |
AU (1) | AU724716B2 (de) |
CA (1) | CA2244110A1 (de) |
DE (1) | DE69716240T2 (de) |
DK (1) | DK0880360T3 (de) |
ES (1) | ES2184990T3 (de) |
PT (1) | PT880360E (de) |
WO (1) | WO1997028818A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
WO2001007062A1 (en) * | 1999-07-26 | 2001-02-01 | Ashok Rajgarhia | A synergistic composition for the treatment of liver and liver associated ailments and a process for preparing the same |
US20050129712A1 (en) * | 2002-03-28 | 2005-06-16 | Hansjorg Reimann | Combined dna/protein vaccine compositions |
RU2311911C2 (ru) | 2002-07-05 | 2007-12-10 | Липоксен Текнолоджиз Лимитед | Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
KR101390072B1 (ko) | 2004-09-14 | 2014-04-30 | 아고스 쎄라퓨틱스, 인코포레이티드 | 병원체의 균주 독립성 증폭 및 그에 대한 백신 |
JP2008534598A (ja) * | 2005-04-01 | 2008-08-28 | ワイス | 免疫原の干渉を克服するための、慣習的なワクチンと組み合わせたdnaワクチンの使用 |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
RU2636455C2 (ru) | 2010-05-14 | 2017-11-23 | Баксалта Инкорпорейтид, (US) | Химерные гены ospa, белки и способы их применения |
US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
MX2013000164A (es) | 2010-07-06 | 2013-03-05 | Novartis Ag | Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn. |
DK3981427T3 (da) | 2010-08-31 | 2022-07-11 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
EP4098325A1 (de) | 2010-10-11 | 2022-12-07 | GlaxoSmithKline Biologicals S.A. | Antigenfreisetzungsplattformen |
ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
RU2015106742A (ru) | 2012-07-27 | 2016-09-20 | Бакстер Интернэшнл Инк. | Композиции, содержащие химерные молекулы ospa и способы их применения |
EP4366762A1 (de) * | 2021-07-05 | 2024-05-15 | Evaxion Biotech A/S | Impfstoffe gegen neisseria gonorrhoeae |
WO2024038407A1 (en) * | 2022-08-19 | 2024-02-22 | Seqirus Inc. | Lipid nanoparticle comprising a dna-binding protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9305759D0 (en) * | 1993-03-19 | 1993-05-05 | Medical Research Council And T | Hiv therapy method and agents |
AU705889B2 (en) * | 1993-08-26 | 1999-06-03 | Regents Of The University Of California, The | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides |
GB9319772D0 (en) * | 1993-09-24 | 1993-11-10 | Therexsys Ltd | Therapeutic agent |
WO1996041606A2 (en) * | 1995-06-08 | 1996-12-27 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
-
1997
- 1997-02-12 AT AT97903448T patent/ATE225668T1/de not_active IP Right Cessation
- 1997-02-12 JP JP9528316A patent/JP2000505802A/ja not_active Ceased
- 1997-02-12 ES ES97903448T patent/ES2184990T3/es not_active Expired - Lifetime
- 1997-02-12 EP EP97903448A patent/EP0880360B1/de not_active Expired - Lifetime
- 1997-02-12 DK DK97903448T patent/DK0880360T3/da active
- 1997-02-12 DE DE69716240T patent/DE69716240T2/de not_active Expired - Fee Related
- 1997-02-12 AU AU18005/97A patent/AU724716B2/en not_active Ceased
- 1997-02-12 PT PT97903448T patent/PT880360E/pt unknown
- 1997-02-12 WO PCT/GB1997/000396 patent/WO1997028818A1/en active IP Right Grant
- 1997-02-12 CA CA002244110A patent/CA2244110A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2244110A1 (en) | 1997-08-14 |
PT880360E (pt) | 2003-02-28 |
AU1800597A (en) | 1997-08-28 |
ATE225668T1 (de) | 2002-10-15 |
DE69716240D1 (de) | 2002-11-14 |
EP0880360A1 (de) | 1998-12-02 |
AU724716B2 (en) | 2000-09-28 |
EP0880360B1 (de) | 2002-10-09 |
ES2184990T3 (es) | 2003-04-16 |
JP2000505802A (ja) | 2000-05-16 |
DK0880360T3 (da) | 2003-01-27 |
WO1997028818A1 (en) | 1997-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69716240T2 (de) | Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten | |
RU2221045C2 (ru) | ОМР26 АНТИГЕН Haemophilus influenzae, КОДИРУЮЩАЯ ЕГО НК И ЕГО ИСПОЛЬЗОВАНИЕ | |
DE69918146D1 (de) | Verfahren zur therapeutischen impfung | |
DE69723434D1 (de) | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope | |
ATE418340T1 (de) | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen | |
Schunk et al. | Applications and optimization of immunization procedures | |
HUP0402048A2 (hu) | Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására | |
CA2325566A1 (en) | Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates | |
HUP0303173A2 (hu) | Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok | |
ME00183B (me) | Novi postupak za deregulaciju amiloida | |
BR9306984A (pt) | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo | |
NO975730L (no) | Metode for ökning av beskyttende immunresponser | |
WO1995032731A2 (en) | Immunogenic pharmaceuticals | |
US20120076818A1 (en) | Immunogenic composition and use thereof | |
WO2003000719A8 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
AU707083B2 (en) | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes | |
Goldblum et al. | Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area. | |
Chowdhury et al. | Generation of high titer antisera in rabbits by DNA immunization | |
AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
WO1999002132A3 (en) | Use of submicron oil-in-water emulsions with dna vaccines | |
WO2002087611B1 (de) | Mittel humanen ursprungs zur vakzination gegen gd2-positive tumore | |
CA1337115C (en) | Vaccination against rabies-related diseases | |
AU2667600A (en) | Identification of specific differentially expressed antigens | |
CA2370278A1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
FR3014103B1 (fr) | Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ML LABORATORIES PLC, LONDON, GB |
|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |